Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana Files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission

Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana Files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission

NEW YORK and LONDON, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces that it has filed a “universal” shelf registration statement on Form F-3 (File No. 333-252441) (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") in relation to up to US$250,000,000 in market value of its securities.

The filing of “universal” shelf registration statements of this type, a common practice by NASDAQ-listed companies, enables issuers to have more timely and efficient access to the U.S. capital markets.

The Registration Statement also contains a preliminary prospectus supplement relating to an “at-the-market” sales agreement, which the Company expects to enter into with B. Riley Securities, Inc. (the “Agent”) on or about the date of this announcement, pursuant to which the Company may sell, from time to time, at its option, up to US$100,000,000 (i.e., up to 40% of those securities registered pursuant to the Registration Statement) in market value of American Depositary Shares representing its ordinary shares through the Agent (the "ATM Program").

For the avoidance of doubt, the Company has no immediate plans to offer or sell any securities pursuant to the Registration Statement or the ATM Program.

The Company notes that the Registration Statement has not yet been declared effective by the SEC, and that the specifics of any future offering pursuant to the Registration Statement (including under the ATM Program), such as the prices and terms of the securities offered, will be determined at the time of any such offering and will be described in detail in a prospectus supplement filed by the Company with the SEC in connection with such offering.

For further enquiries:

United Kingdom:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder
+44 (0)20 7495 2379